Medtech stocks made a run at a new peak over the past week, but ultimately remained mostly unchanged from the previous seven days. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — finished last week at 89.3 (Sep. 18), marking a 0.3% gain from the 89.03 points registered at […]
Intersect ENT
Intersect ENT to acquire Fiagon for $71.1M
Intersect ENT (NSDQ:XENT) announced today that it entered into an agreement to acquire Fiagon AG Medical Technologies for $71.1 million. The $71.1 million (€60 million) cash deal will see Intersect ENT make an initial $17.8 million (€15 million) payment at the time of closing and further $17.8 (€15 million) annual payments over the following three years. […]
Intersect ENT up on mixed bag Q2 results
Intersect ENT (NSDQ:XENT) posted second-quarter results today that beat the revenue consensus on Wall Street but missed on earnings. The Menlo Park, Calif.-based company report losses of -$223.1 million, or -71¢ per share, on sales of $9.8 million for the three months ended June 30, for a bottom-line sales loss of -63.3% compared with Q2 2019. […]
MedTech 100 roundup: Medtech stocks bump along
Medical device company stocks appear to be in a holding pattern as investors wait for new earnings reports. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — bumped along last week. It closed at 84.39, about where it had been at the start of the week. The Dow Jones […]
Report: Medtronic makes a bid for Intersect ENT
Intersect ENT (NSDQ:XENT) shares soared today on news that Medtronic (NYSE:MDT) has made a bid for the Menlo Park, Calif.-based ear, nose and throat condition treatment developer. Bloomberg reported the transaction late Tuesday, attributing the news to “people with knowledge of the matter.” Traders sent Intersect ENT shares up 38% in premarket trading. Medtronic declined to comment. […]
Intersect ENT’s Q4 beats Street despite losses
Intersect ENT (NSDQ:XENT) shares dipped today on fourth-quarter losses that topped the consensus forecast. The Menlo Park, Calif.-based ear, nose and throat condition treatment developer posted losses of -$7.96 million, or -25¢ per share, on sales of $31.75 million for the three months ended Dec. 31, 2019, for a nearly $3 million bottom-line slide on a […]
